Cefonicid monosodium
Cefonicid monosodium is a long-acting cephalosporin antibiotic. Cefonicid monosodium also acts as a noncompetitive class I β-lactamase inhibitor with a Ki value of 0.8 μM. Cefonicid monosodium exhibits broad-spectrum antimicrobial activity and is effective against a variety of Gram-positive and Gram-negative bacteria. Cefonicid monosodium can be used for research on infections.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- CAS. Nr.: 71420-79-6
- Formel: C18H17N6NaO8S3
- Molecular Weight:564.55
-
Speicherung:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biologische Aktivität
-
Chemical Information
- Protokoll
- Reinheit & Dokumentation
- Verweise
-
Help & FAQs
Alle Antibiotic Isoform-spezifische Produkte anzeigen
MoreAlle Beta-lactamase Isoform-spezifische Produkte anzeigen
More
Biologische Aktivität
Beschreibung
In Vitro
Cefonicid (25-200 mg/L; 3-6 days) monosodium dose-dependently inhibits the proliferation of human PBMCs stimulated by FLU, XENO, ALLO, and PHA (HY-N7038)[1].
Cefonicid (0-200 mg/L; 7 days) monosodium dose-dependently inhibits IL-2 production by human PBMC stimulated with FLU, XENO and ALLO[1].
Cefonicid (0-24 h) monosodium exhibits concentration-dependent bactericidal activity against Klebsiella pneumoniae strain 2603 in vitro, with an MIC of 0.25 mg/L[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
Cefonicid (40 mg/kg; single dose) monosodium exhibits excellent protective effects against S. aureus, E. coli, P. mirabilis, and K. pneumoniae infections in mice[4].
Cefonicid monosodium exerts excellent preventive protective effects against surgical wound infections in mice, with an ED50 value of ≤2.1 mg/kg against Gram-negative bacilli and an ED50 value ranging from 3.7 to 8.7 mg/kg against S. aureus[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Hartley (female, 220-250 g)[3]
-
Dosage:15 mg/kg
-
Administration:i.p.; 2 doses (immediately and 24 hours post-challenge)
-
Result:Showed similar lung bacterial counts to infected untreated controls at 0 and 1 hour post-challenge.
Reduced lung bacterial counts significantly compared to infected untreated controls starting at 6 hours post-challenge, with significant reductions also seen at 24 and 48 hours post-challenge.
Chemical Information
-
CAS. Nr. 71420-79-6
-
Molecular Weight 564.55
-
Formel C18H17N6NaO8S3
-
SMILES
O=C(O)C(N12)=C(CSC3=NN=NN3CS(=O)(O[Na])=O)CS[C@]2([H])[C@H](NC([C@H](O)C4=CC=CC=C4)=O)C1=O
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
Please store the product under the recommended conditions in the Certificate of Analysis.
Reinheit & Dokumentation
Verweise
[1]. Villa ML, et al. Interference of cephalosporins with immune response: effects of cefonicid on human T-helper cells. Int J Immunopharmacol. 1991;13(8):1099-1107. [Content Brief]
[4]. Saltiel E, et al. Cefonicid. A review of its antibacterial activity, pharmacological properties and therapeutic use. Drugs. 1986;32(3):222-259. [Content Brief]
Calculators
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
Cefonicid monosodium Related Classifications
HY-B1300B Related Classifications
Powered by Bioz